Candel Therapeutics
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Candel Therapeutics sits in the top decile of US sponsors by registered trial count (#1,049 of 15,742 sponsors by registered trial count).
Candel Therapeutics: 13 sponsored US clinical trials, 2 recruiting.
Candel Therapeutics sponsors 13 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 7 completed. 2 of these trials are in Phase 3-4 (later-stage) and 11 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Prostate Cancer, with 2 trials.
Top-decile sponsor footprint
Candel Therapeutics ranks in the top decile of sponsors by registered trial count (#1,049 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Open and recent trials
13 total, page 1 of 1
Aglatimagene Besadenovec + Prodrug and Pembrolizumab vs Docetaxel for Stage IV Non-Squamous NSCLC Progressing on Pembrolizumab (AURORA)
NCT07660094
A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene Besadenovec
NCT07332000
CAN-2409 Plus Prodrug With Standard of Care Immune Checkpoint Inhibitor for Stage III/IV NSCLC
NCT04495153
Randomized Controlled Trial of CAN-2409 Immunotherapy During Active Surveillance for Prostate Cancer (ULYSSES)
NCT02768363
Neoadjuvant CAN-2409 in Combination With Chemoradiation or SBRT for Borderline Resectable Pancreatic Adenocarcinoma
NCT02446093
Phase 3 Study of ProstAtak® Immunotherapy With Standard Radiation Therapy for Localized Prostate Cancer
NCT01436968
GMCI, Nivolumab, and Radiation Therapy in Treating Patients With Newly Diagnosed High-Grade Gliomas
NCT03576612
Intratumoral Gene Mediated Cytotoxic Immunotherapy in Patients With Resectable Non-Small Cell Lung Cancer
NCT03131037
Intrapleural AdV-tk Therapy in Patients With Malignant Pleural Effusion
NCT01997190
A Phase I Study of AdV-tk + Prodrug Therapy in Combination With Radiation Therapy for Pediatric Brain Tumors
NCT00634231
AdV-tk Therapy With Surgery and Chemoradiation for Pancreas Cancer (PaTK01)
NCT00638612
Phase 2a Study of CAN-2409 With Standard Radiation Therapy for Malignant Glioma
NCT00589875
Phase 1b Study of AdV-tk + Valacyclovir Combined With Radiation Therapy for Malignant Gliomas
NCT00751270
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 6 |
| Phase 2 | 5 |
| Phase 3 | 2 |
What is open in the Candel Therapeutics pipeline
2 recruiting of 13 indexed (15% open); 7 completed (54%).
Phase mix: 2 late (III/IV) vs 11 early (I/II) (early-phase heavy).
Top condition: Prostate Cancer (2 trials), 4 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Candel Therapeutics: open-pipeline peers nationwide
Peers matched on 13 registered trials and 15% open enrollment, not the therapeutic-area sidebar.
Candel Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 13 trials (± recruiting share)
- Adaptimmune · 13 trials · 0% recruiting
- Agennix · 13 trials · 0% recruiting
- Akili Interactive Labs · 13 trials · 0% recruiting
- Alumis · 13 trials · 8% recruiting
Sponsors near 15% open enrollment (± trial volume)
- Arrowhead Regional Medical Center · 15% recruiting · 13 trials
- Aurinia Pharmaceuticals · 15% recruiting · 13 trials
- Bronx VA Medical Center · 15% recruiting · 13 trials
- Dicerna Pharmaceuticals, Inc., a Novo Nordisk company · 15% recruiting · 13 trials
Related
What to do with this Candel Therapeutics page
13 registered trials is a research-attention snapshot, not an endorsement of Candel Therapeutics or any single study.
- 2 of Candel Therapeutics's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Prostate Cancer is the condition Candel Therapeutics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Prostate Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Candel Therapeutics pipeline card: 13 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.